Short answer
ACADIA PHARMACEUTICALS INC (ACAD) filed an 8-K current report with the SEC on May 29, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 5.07 (Submission of Matters to a Vote of Security Holders). 2026 Annual Meeting held May 29, 2026.
ACADIA PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- 2026 Annual Meeting held May 29, 2026
Item 5.07 · Submission of Matters to a Vote of Security Holders
- Three Class I directors elected through 2029, with James M. Daly receiving the strongest support at 146.9M votes
- Executive compensation approved, with 148.3M votes for and 1.9M against
- Ernst & Young LLP ratified as independent auditor for fiscal 2026, with 157.4M votes for
- Equity plan expanded by 5,209,670 authorized shares, creating additional potential dilution capacity
- 10,356,394 broker non-votes on director, compensation, and plan proposals limited voting participation
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ACADIA PHARMACEUTICALS INC 8-K filings
Get the next ACAD 8-K as it lands
Follow ACAD for push alerts, or ask the research agent what this filing means.